Alliance A071701: Genomically guided treatment trial in brain metastases., page-13

"So primary cancer, high level reviews underway, very probably ......Just another likely major plus for this stock, with its woeful share price"
.
Yes, the researchers should be able to identify the presence of the PI3K enzymes, together with the presence of the Paxalisib inhibitor in the primary cancer of the patients for the duration of the trial.
Another controlled trial opportunity to validate Paxalisib's huge potential.
Good work needle.

Regards.